Disclaimer: The University of Toronto is not responsible for the content linked to the logos displayed on this page.
ICNMD 2016 would like to thank the following companies for their generous support:
See floorplan below.
|Booth #: 110||Alexion is a global biopharmaceutical company focused on life-transforming therapies for patients with devastating, rare diseases. Alexion developed the first and only approved complement inhibitor for PNH & aHUS. The Company is strengthening and broadening its complement portfolio, including evaluating complement inhibition in additional ultra-rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for two ultra-rare, life-threatening disorders.(www.alexion.com)|
|Booth #: 115-116||Baxalta Incorporated (NYSE: BXLT) is a global biopharmaceutical company developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology and oncology. Launched in 2015, following its separation from Baxter, Baxalta’s therapies are available in more than 100 countries. Baxalta is headquartered in Northern Illinois. (www.baxalta.com)|
|Booth #: 108||Since 1979, Cadwell has been achieving growth by responding to the needs of our end users and focusing on our core competencies. We continually develop our main solutions: EMG, IONM, EEG, Sleep, Consumables, and CadLink Data Enterprise. We are a globally focused company with worldwide business partners and clinical specialists. (www.cadwell.com)|
|Booth #: 113||CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself. (www.cslbehring.ca)|
|Booth #: TT5||Improves the quality of life for individuals and families affected with GBS, CIDP, MMN, and variants. Serving patients with support, education, research, and advocacy. GBS is an inflammatory disorder of the peripheral nerves that affects 2 in 100,000 individuals, while CIDP, a chronic condition, can affect as high as 9 in 100,000 individuals. (www.gbs-cidp.org)|
|Booth #: 105||GeneDx is a highly respected laboratory, specializing in genetic testing for inherited disorders. GeneDx offers next-generation sequencing and deletion/duplication testing for inherited cardiac disorders, mitochondrial disorders, neurological disorders, inherited cancer disorders, prenatal disorders and other rare genetic disorders. GeneDx also offers whole exome sequencing and microarray-based testing. (www.GeneDx.com)|
|Booth #: 107||Grifols is a global healthcare company founded in 1940, currently present in more than 100 countries worldwide and headquartered in Barcelona, Spain. In 2015 Grifols celebrates its 75th Anniversary of improving people’s health and well-being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products. (www.grifols.com)|
|Booth #: TT4||IOS Press, established in 1987, publishes around 100 international journals and approximately 90 book titles a year, in a broad range of subjects. IOS Press has a strong neurosciences package, which includes Journal of Alzheimer’s Disease (Impact Factor 4.151, according to JCR 2014), Journal of Neuromuscular Diseases, Journal of Parkinson’s Disease and Journal of Huntington’s Disease. (www.iospress.com)|
|Booth #: 102||LFB is a leading European pharmaceutical group specializing in biological medicines, under hospital prescription, for serious and often rare diseases. LFB’s products are currently marketed in more than 40 countries. (www.lfb.fr/en/home.html)|
|Booth #: 106||LifeLabs is a Canadian-owned company with over 50 years of experience providing laboratory testing services to help healthcare providers diagnose, treat, monitor and prevent disease. LifeLabs Genetics is the largest privately owned genetics laboratory in Canada, offering more than 2,000 genetic and biochemical tests. (www.lifelabs.com)|
|Booth #: TT2||Muscular Dystrophy Canada is at the heart of an active community of people across Canada who are affected by neuromuscular disorders. Our goal is to build a world without neuromuscular disorders and enhance the lives of Canadians with neuromuscular disorders by giving them the information, tools and support they need while we relentlessly search for new therapies and a cure. (www.muscle.ca)|
|Booth #: TT3||Myasthenia Gravis Society of Canada (MG Canada) seeks universal access for MG diagnosis and treatment for all Canadians. MG Canada is committed to advancing education and support for MG patients, MG caregivers and MG Health Professionals, and to encourage research for MG patient quality lifestyle and the quest for cure. (www.mgcanada.org)|
Booth #: TT3-B
|Myositis/Myosite Canada is a non-profit, volunteer organization dedicated to improving the lives of people affected by myositis. It is governed by a Board that brings diverse strengths and perspectives. Mission: To support people with Myositis, caregivers, researchers and health care providers in diagnosing, treating, and rehabilitating Myositis people. (www.myositis.ca/node/2)|
|Booth #: 112||PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of novel orally administered drugs that target RNA mechanisms affecting protein production. It is PTC’s mission to bring new therapies to patients affected by rare and neglected diseases such as cystic fibrosis and Duchenne muscular dystrophy. (www.ptcbio.com)|
|Booth #: TT1||Founded in 2014, the RYR-1 Foundation supports research to find an effective treatment or a cure for RYR-1 related myopathy. The Foundation also provides resources for physician education, patient education, and patient advocacy. To learn more, please visit www.ryr1.org.|
|Booth #: 111||Sanofi Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. Visit www.genzyme.com.|
|Booth #: 117||Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of prescription drugs to treat mitochondrial and neuromuscular diseases. The company is passionate about improving patients’ quality of life and is well underway to become an industry leader in the treatment of rare diseases. (www.santhera.com)|
|Booth #: 109||Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. (www.terumobct.com)|
|Booth #: TT6||TREAT-NMD is a network for the neuromuscular field that provides an infrastructure to ensure that the most promising new therapies reach patients quickly. Since its launch in January 2007 the network’s focus has been on the development of tools that industry, clinicians and scientists need to bring novel therapeutic approaches through preclinical development and into the clinic, and on establishing best-practice care for neuromuscular patients worldwide. (www.treat-nmd.eu)|
|Booth #: 103||Ultragenyx is a development-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases. Ultragenyx has licensed rights to aceneuramic acid extended release and its potential use in treating GNE Myopathy from Nobelpharma, AAI Pharma, and the HIBM Research Group. (www.ultragenyx.com)|
(Click to download)
Please be aware that you may receive phone calls or emails from organizations who will claim to be calling on behalf of the ICNMD 2016 Congress and will offer discounted hotel rates to delegates in Toronto, Canada. They will request a contract and payment information from you to take advantage of their alleged discounts.
These companies are NOT affiliated with the Congress and you should not, under any circumstances, provide them with your payment information.
Should you have booked with one of these organizations, please inform the Registration & Housing Department of ICNMD 2016 at ICNMD2016-Registration at icsevents.com.
The Congress Secretariat (International Conference Services Ltd.) is the official housing bureau for ICNMD 2016 and is offering assistance with the coordination of housing requirements for the Congress. Special rates and added complimentary amenities will only be available to delegates and exhibitors who book through the Congress Secretariat.
You will have the opportunity to book your rooms with the Congress Secretariat when registering for the Congress, upon receiving a special link sent to you by email by the Sponsorship & Exhibit Manager. You will not be asked to book your room on the phone and you will not be asked for a 30% deposit upon booking.
The ICNMD 2016 Congress and its supporting organizations cannot meet the contracted room obligations if sponsors, exhibitors and delegates book outside the block of the official housing bureau. Rooms that are not filled because of that create an expense for the Congress in form of financial penalties (attrition charges) and place the financial success of the Congress at risk, which increases with each delegate, exhibitor and sponsor not booking through the official housing bureau.